Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
- PMID: 18242319
- DOI: 10.1016/j.pcl.2007.10.015
Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
Abstract
The past 25 years have seen an increase in our understanding of immunology and further expansion in the clinical use of immunotherapeutic modalities. How immunotherapy will be integrated with chemotherapy, radiation, and surgery remains to be established. Although there have been successes in the field of immunotherapy, they have been inconsistent, and it is hoped that increased understanding of the basic principles of immunology will improve the consistency of beneficial effects. In this article, we briefly provide a general overview of our current understanding of the immune system, with a focus on concepts in tumor immunology, followed by a discussion of how these concepts are being used in the clinic.
Similar articles
-
Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?Hematol Oncol Clin North Am. 2010 Feb;24(1):109-27. doi: 10.1016/j.hoc.2009.11.010. Hematol Oncol Clin North Am. 2010. PMID: 20113898 Review.
-
Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?Arch Immunol Ther Exp (Warsz). 2002;50(3):197-224. Arch Immunol Ther Exp (Warsz). 2002. PMID: 12098935 Review.
-
[Oncoimmunology: some fundamental problems of cancer immunotherapy].Mol Biol (Mosk). 2007 Mar-Apr;41(2):355-68. Mol Biol (Mosk). 2007. PMID: 17514902 Review. Russian.
-
Cancer vaccine development: on the way to break immune tolerance to malignant cells.Exp Cell Res. 2004 Oct 1;299(2):267-78. doi: 10.1016/j.yexcr.2004.06.017. Exp Cell Res. 2004. PMID: 15350526 Review.
-
[Immunotherapy for cancer--modern immunologic strategies in oncology].Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Dtsch Med Wochenschr. 2008. PMID: 18985564 Review. German.
Cited by
-
Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.Front Oncol. 2022 May 19;12:864301. doi: 10.3389/fonc.2022.864301. eCollection 2022. Front Oncol. 2022. PMID: 35664731 Free PMC article. Review.
-
Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.Cancer Immunol Immunother. 2015 May;64(5):573-83. doi: 10.1007/s00262-015-1657-9. Epub 2015 Feb 18. Cancer Immunol Immunother. 2015. PMID: 25854581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
